4D Molecular Therapeutics misses earnings estimates
Gene therapy company reports $514M cash position, completes Phase 3 enrollment ahead of schedule
4D Molecular Therapeutics reported a wider-than-expected loss for fiscal 2025 on Wednesday, though investors focused on the gene therapy company's strong cash position and accelerated clinical trial progress as shares held steady in after-hours trading.
The Emeryville, California-based company posted a net loss of $140 million, or $2.42 per share, for the full year ended December 31, compared with a loss of $161 million, or $2.98 per share, in 2024. Analysts had anticipated a loss of $0.98 per share, according to consensus estimates compiled by Zacks Investment Research. The 146% earnings miss reflected elevated research and development spending tied to the company's advancing clinical programs.
Despite the headline earnings shortfall, several metrics pointed to improving fundamentals. Total revenue reached $85.2 million for the year, up from zero in the prior year, driven entirely by an upfront payment from the Otsuka Pharmaceutical collaboration agreement. The partnership, announced in 2024, provides development and commercialization rights for 4D-150, the company's experimental gene therapy for wet age-related macular degeneration (AMD).
Research and development expenses surged to $196 million from $141 million in 2024, primarily to fund the 4D-150 Phase 3 clinical trials. Even with the increased spending, the company narrowed its operating loss to $159.5 million from $187.8 million year-over-year.
Perhaps most significantly for investors, 4D Molecular Therapeutics ended 2025 with $514 million in cash, cash equivalents, and marketable securities. Management indicated this position, combined with anticipated payments from Otsuka, should fund operations into the second half of 2028, providing a substantial runway for multiple clinical readouts.
The company's operational highlights dominated the investor narrative. 4D Molecular Therapeutics announced completion of enrollment in the 4FRONT-1 Phase 3 trial for 4D-150 in February, with more than 500 patients randomized. The trial reached full enrollment approximately 11 months after launch, ahead of initial projections and reflecting what management described as strong investigator and patient interest.
"The rapid enrollment completion of our 4FRONT-1 Phase 3 trial underscores the significant need for new treatments for wet AMD and the potential of 4D-150 to transform the treatment paradigm," the company stated in its earnings announcement.
The 4FRONT-2 global Phase 3 trial remains on track to complete enrollment in the second half of 2026, with site activations accelerating across Europe and the Asia-Pacific region. Both trials have increased their target enrollment from 400 to 480 patients to bolster potential for global regulatory approvals.
Topline data from the 4FRONT-1 trial is expected in the first half of 2027, with 4FRONT-2 results anticipated in the second half of that year. Additional pipeline milestones include two-year data from the PRISM Phase 2b wet AMD study at a scientific conference in mid-2026, two-year data from the SPECTRA Phase 1/2 diabetic macular edema trial in the second half of 2026, and initiation of a global Phase 3 DME trial in the third quarter of 2026.
Analysts maintained a largely positive outlook on the stock despite the earnings miss. According to MarketBeat data, the company carries a consensus rating of "Moderate Buy" with an average price target of $33.11—roughly 287% above Wednesday's closing price of $8.56. Of 11 analysts covering the stock, nine rate it a Buy or Strong Buy, while two recommend Hold.
The biotechnology sector has faced heightened scrutiny in recent months as investors weigh clinical progress against cash burn rates in a still-challenging financing environment. 4D Molecular Therapeutics' substantial cash position and the accelerated enrollment timeline for its lead program may provide some insulation from these broader headwinds.
Wet AMD represents a significant commercial opportunity, with current standard-of-care treatments requiring frequent injections into the eye. A successful gene therapy could potentially provide durable vision improvement with a single administration, representing a transformative advancement for patients and a multi-billion dollar market opportunity for 4D Molecular Therapeutics and partner Otsuka.
Shares were down 0.4% in extended trading following the announcement, having closed the regular session at $8.56. The stock has traded within a 52-week range of $2.24 to $12.34 and carries a market capitalization of approximately $485 million.